tablets Livostor are applied at indications which are provided below.

Prevention of cardiovascular diseases:

• for:
  • reduction of risk of developing of a myocardial infarction;
  • reduction of risk of developing of a stroke;
  • reduction of risk of stenocardia and holding procedures of revascularization;
• to patients with diabetes ІІ like and without clinically apparent coronary heart disease, but with several risk factors of developing coronary heart disease, such as retinopathy, albuminuria, tobacco smoking or arterial hypertension, medicine for:
  • reduction of risk of developing of a myocardial infarction;
  • reduction of risk of developing of a stroke;
to patients with clinically apparent coronary heart disease medicament is shown to
• for:
  • reduction of risk of developing of a non-lethal myocardial infarction;
  • reduction of risk of developing of a lethal and non-lethal stroke;
  • reduction of risk of holding procedures of revascularization;
  • reduction of risk of hospitalization in connection with stagnant heart failure;
  • reduction of risk of developing of stenocardia.

Lipidemia:

• as addition to a diet for reduction of the increased levels of the general cholesterol, LDL cholesterol, apolipoprotein B and triglycerides and also for increase in level of LPVP cholesterol at patients with primary hypercholesterolemia (heterozygous family and single) and the mixed dislipidemiya (the IIa and IIb types on Fredrikson's classification);
• as addition to a diet for treatment of patients with the increased levels of triglycerides in blood serum (type IV on Fredrikson's classification);
• for treatment of patients with primary disbetalipoproteinemiya (type III on Fredrikson's classification) in cases when observance of a diet is insufficiently effective;
• for reduction of the general cholesterol and LDL cholesterol at patients with a homozygous family hypercholesterolemia as addition to other hypolipidemic methods of treatment (for example, aferez LDL) or if such methods of treatment are inaccessible;
• as addition to a diet for reduction of levels of the general cholesterol, LDL cholesterol and apolipoprotein B at boys and also girls after the beginning of periods, aged from 10 up to 17 years with a heterozygous family hypercholesterolemia, if after the corresponding dietotherapy results of analyses such: LDL cholesterol remains ≥ 190 mg/dl or LDL cholesterol ≥ 160 mg/dl and: in the family anamnesis there are early cardiovascular diseases or the patient of children's age has two or more other risk factors of developing cardiovascular diseases.

Structure

Active ingredient: atorvastatin;

1 tablet supports an atorvastatin of calcium of trihydrate that is equivalent to an atorvastatin of 10 mg or 20 mg, or 40 mg;

Excipients: hydroxypropyl cellulose, polysorbate-80, sodium lauryl sulfate, lactoses monohydrate, calcium carbonate, cellulose microcrystalline, sodium of a kroskarmelloz, magnesium stearate;

Cover: mix for a film covering of Opadry II White (a gipromelloz, lactose monohydrate, polyethyleneglycol, the titan dioxide (E 171), triacetin).

Contraindication

• an active disease of a liver which can include permanent increase in levels of hepatic transaminases of an unknown etiology;
• hypersensitivity to any of medicine components.

Route of administration

Recommended initial medicament dose Livostor makes 10 or 20 mg of 1 times a day. For the patients needing considerable decrease in level of LDL cholesterol (more than for 45%), therapy can be begun with a dosage of 40 mg of 1 times a day. Range of medicament doses Livostor is ranging from 10 up to 80 mg of 1 times a day. Medicine can be accepted a single dose in any hours and irrespective of meal. The initial and supporting medicament doses Livostor should be selected individually, depending on the purpose of treatment and the answer to it. After an initiation of treatment and/or after titration of a medicament dose Livostor it is necessary to analyze levels of lipids during the period from 2 to 4 weeks and as appropriate to modify a dose.

Feature of use

Pregnant

Livostor is contraindicated to pregnant women and women who can become pregnant.

Children

did Not reveal significant influence of medicine on growth or puberty of boys or on duration of a menstrual cycle at girls. Teenage girls should be consulted rather acceptable methods of contraception during the treatment period Livostor medicine. Researches of use of medicine for patients of prepubertatny age or patients aged up to 10 years were not conducted.

Drivers

Medicine has very insignificant impact on speed of response during control of motor transport or work with other mechanisms.

Overdose

Specific treatment of overdose. In case of overdose of the patient it is necessary to treat symptomatic and if necessary to hold the supporting events. Because of high extent of linking of medicine with proteins of blood plasma it is not necessary to expect considerable strengthening of clearance of Livostor medicine by means of a hemodialysis.

Side effects

• from nervous system: headache; dizziness, paresthesia, hypesthesia, dysgeusia, amnesia; peripheral neuropathy; dreadful dreams; depression.
• from digestive tract: constipation; pancreatitis, vomiting; gastrointestinal discomfort, eructation, meteorism; abdominal pain.
• from a skeletal and muscular system and connective tissue: joint pain, dorsodynia; myopathy, miositis, rhabdomyolysis; musculoskeletal pain, increased fatigue of muscles, neck pain, swelling of joints, a tendinopatiya (sometimes complicated by a rupture of a sinew); arthralgia.
• from metabolism and food: hypoglycemia, increase in body weight, anorexia; hyperglycemia.
• from a liver and a gall bladder: liver failure; hepatitis, cholestasia.
• from skin and connective tissue: skin rashes, itching, alopecia; Quincke's disease, bullous dermatitis (including multiformny erythema), Stephens-Johnson's syndrome and toxic epidermal necrolysis; small tortoiseshell.
• from the respiratory system, bodies of a thorax and mediastinum: sore throat and throats; nasal bleeding; exceptional cases of an interstitial disease of lungs (especially during long-term treatment).
• from the system of blood and lymphatic system: thrombocytopenia.
• from the immune system: allergic reactions; anaphylaxis.
• from organs of sight: misting of sight; disorder of vision.
• from organs of hearing and balance: sonitus.
• from an urinogenital system: leukocyturia.
• from a reproductive system and mammary glands: gynecomastia.

Interaction

Cimetidinum. Signs of interaction of an atorvastatin and Cimetidinum are not revealed.

Antacids. Concomitant oral administration of an atorvastatin and suspension of antiacid medicine, the containing magnesium and aluminum hydroxide, is followed by decrease in concentration of an atorvastatin in blood plasma approximately for 35%. At the same time hypolipidemic action of an atorvastatin does not change.

Kolestipol. Concentration of an atorvastatin in blood plasma is lower (approximately for 25%) at a concomitant use of an atorvastatin and a kolestipol. At the same time hypolipidemic action of a combination of an atorvastatin and kolestipol exceeds effect which can be received from reception of each of these medicines separately.

Azithromycin. Co-administration of an atorvastatin (10 mg of 1 times a day) and azithromycin (500 mg of 1 times a day) is not followed by changes of concentration of an atorvastatin in blood plasma.

to Store

in original packing at a temperature not above 25 °C, out of children's reach.

Expiration date - 3 years.